ProGenis Pharmaceuticals is proud to welcome Professor Girish Dwivedi as its new Clinical Advisor for Cardiovascular Diseases. A highly respected cardiologist and researcher, Professor Dwivedi brings world-class expertise in multimodality cardiac imaging and cardiovascular innovation.
Professor Dwivedi currently serves as the inaugural Wesfarmers Chair in Cardiology at The University of Western Australia (Harry Perkins Institute of Medical Research) and as a Consultant Cardiologist at Fiona Stanley Hospital, where he also leads clinical innovation. Prior to this, he was a Clinician Scientist and Consultant Cardiologist at the University of Ottawa Heart Institute in Canada, further enriching his global perspective on cardiac care.
With a distinguished background in Level 3 multimodality cardiac imaging, Professor Dwivedi holds accreditations in Cardiac CT, Echocardiography, Cardiac MRI, and Nuclear Cardiology (including PET) from leading international boards. His expertise in non-invasive imaging has played a crucial role in advancing the early detection and diagnosis of cardiovascular diseases.
Professor Dwivedi’s research has significantly contributed to understanding myocardial contrast echocardiography and radionuclide myocardial perfusion imaging, particularly in acute myocardial infarction. His PhD research at the University of Manchester (UK) provided key insights into left bundle branch block’s impact on SPECT imaging and its implications for diagnosing coronary artery disease, with findings published in prestigious journals such as JACC and Circulation.
At ProGenis Pharmaceuticals, Professor Dwivedi’s expertise will be invaluable in shaping innovative strategies for cardiovascular health. His leadership in clinical research and imaging technology will support our commitment to advancing patient care and developing new approaches to diagnosing and treating heart disease.
We are honoured to welcome Professor Girish Dwivedi to our advisory team and look forward to his contributions in driving cardiovascular innovation.